Three defects which have been observed with aging are increased vascular stiffness, depressed responsiveness to catecholamines, and depressed cardiac function. Derangements in adrenergic signaling may presage dysfunction in the cardiac and vascular systems that is induced by the aging process. There are three major components to this study: 1) that altered adrenergic control of vasoactivity precedes increased stiffness in the aged vasculature; 2) that altered adrenergic control of left ventricular (LV) function presages the decline in LV function in the aged heart; and 3) that changes in cardiac and vascular structure in the aging heart are responsible for altered vascular and LV function, but these changes are not necessary for altered adrenergic signaling. To address these components the alterations in arterial pressure/dimension relations, LV function and altered adrenergic signaling with aging will be determined in conscious, chronically instrumented monkeys. The alterations in aging at the cellular and molecular level and histologic alterations in cardiac and vascular structure will be examined. These studies will be conducted in 4 groups of monkeys: 1) younger adults (3-5 years); 2) mature adults (7-10 years); 3) older adults (15-19 years); and 4) senescent adults (older that 20 years).

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
7R01AG014121-04
Application #
6043070
Study Section
Cardiovascular and Pulmonary Research A Study Section (CVA)
Program Officer
Dutta, Chhanda
Project Start
1996-09-30
Project End
2000-06-30
Budget Start
1999-09-30
Budget End
2000-06-30
Support Year
4
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Pennsylvania State University
Department
Physiology
Type
Schools of Medicine
DUNS #
129348186
City
Hershey
State
PA
Country
United States
Zip Code
17033
Vatner, Dorothy E; Yan, Lin; Lai, Lo et al. (2015) Type 5 adenylyl cyclase disruption leads to enhanced exercise performance. Aging Cell 14:1075-84
Iwatsubo, Kosaku; Bravo, Claudio; Uechi, Masami et al. (2012) Prevention of heart failure in mice by an antiviral agent that inhibits type 5 cardiac adenylyl cyclase. Am J Physiol Heart Circ Physiol 302:H2622-8
Guellich, Aziz; Gao, Shumin; Hong, Chull et al. (2010) Effects of cardiac overexpression of type 6 adenylyl cyclase affects on the response to chronic pressure overload. Am J Physiol Heart Circ Physiol 299:H707-12
Depre, Christophe; Park, Ji Yeon; Shen, You-Tang et al. (2010) Molecular mechanisms mediating preconditioning following chronic ischemia differ from those in classical second window. Am J Physiol Heart Circ Physiol 299:H752-62
Ho, David; Yan, Lin; Iwatsubo, Kousaku et al. (2010) Modulation of beta-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5. Heart Fail Rev 15:495-512
Shen, Weiqun; Vatner, Dorothy E; Vatner, Stephen F et al. (2010) Progressive loss of creatine maintains a near normal DeltaG approximately (ATP) in transgenic mouse hearts with cardiomyopathy caused by overexpressing Gsalpha. J Mol Cell Cardiol 48:591-9
Vatner, Stephen F; Yan, Lin; Ishikawa, Yoshihiro et al. (2009) Adenylyl cyclase type 5 disruption prolongs longevity and protects the heart against stress. Circ J 73:195-200
Hu, Che-Lin; Chandra, Rachna; Ge, Hui et al. (2009) Adenylyl cyclase type 5 protein expression during cardiac development and stress. Am J Physiol Heart Circ Physiol 297:H1776-82
Wu, Changgong; Yan, Lin; Depre, Christophe et al. (2009) Cytochrome c oxidase III as a mechanism for apoptosis in heart failure following myocardial infarction. Am J Physiol Cell Physiol 297:C928-34
Park, Misun; Shen, You-Tang; Gaussin, Vinciane et al. (2009) Apoptosis predominates in nonmyocytes in heart failure. Am J Physiol Heart Circ Physiol 297:H785-91

Showing the most recent 10 out of 71 publications